Research Spending Is Treated as Waste by the Accounting Rules
Money spent inventing something is expensed immediately, so the most research intensive companies report artificially low profits and artificially small balance sheets.
The Convention
Under US accounting standards, research and development costs are expensed as incurred. The spending hits the income statement in the year it happens and no asset is recorded, regardless of how confident the company is that the work will produce something valuable.
This is deliberate. The standard setters concluded that the future benefit of research is too uncertain and too difficult to measure reliably to permit capitalisation, and that a conservative rule applied uniformly is preferable to one that depends on management optimism.
The rule is not a claim that research has no future value. It is a judgement that the value is too unreliable to measure, so the conservative treatment is applied to all of it.
What This Does to Reported Numbers
The effect is largest for the companies that invest most heavily in innovation, which is to say the ones creating the most future value.
| Effect | Consequence |
|---|---|
| Earnings understated during heavy investment | Growth companies look less profitable |
| No asset recorded | Balance sheet omits the main value driver |
| Equity understated | Return on equity appears inflated |
| Comparability distorted | Research heavy and research light firms not comparable |
The return on equity effect deserves attention because it runs opposite to intuition. Expensing research reduces both reported profit and accumulated equity. Since equity falls proportionally more over time, the ratio of profit to equity can end up higher than it would be under capitalisation, making a research intensive company look more efficient at using capital than it is.
The Asymmetry That Distorts Comparison
A company that develops a technology internally records no asset. A company that acquires the same technology by buying the business that made it records an identifiable intangible on its balance sheet and amortises it.
Two companies can therefore own economically identical assets and present entirely different financial statements based solely on whether they built or bought. The acquirer shows a larger balance sheet and lower earnings from amortisation. The internal developer shows a smaller balance sheet and, once the spending stabilises, higher earnings.
This is one of the clearest cases where accounting treatment depends on transaction form rather than economic substance.
The International Difference
International standards split the question. Research costs, aimed at gaining new knowledge without a specific product yet, are expensed. Development costs are capitalised when the company can demonstrate technical feasibility, intention to complete, ability to use or sell the result, probable future economic benefit and reliable measurement of the cost.
In practice this means European and other international filers capitalise more development spending than US filers, so profit and asset comparisons between them require adjustment.
How Investors Compensate
The common analytical correction is to capitalise research spending manually. The method estimates a useful life, typically three to ten years depending on industry, treats historical spending as an asset amortised over that life, and adjusts both earnings and equity accordingly.
The result is a research asset on an adjusted balance sheet and an earnings figure that reflects amortisation of past spending rather than the full current year outlay. This makes research intensive and research light companies more comparable and produces return on capital figures that are less flattering and more meaningful.
The weakness is that the useful life is assumed rather than observed, and the answer is sensitive to it. Research productivity varies enormously between firms, and treating all spending as equally productive is its own simplification.
Why the Rule Survives
Despite persistent criticism, the expensing convention has proven durable, and the reason is instructive. Permitting capitalisation would hand management a lever over reported earnings at exactly the moment they are most motivated to use it. A company under pressure could capitalise more aggressively and manufacture profit growth from an accounting choice.
The rule trades relevance for reliability. It produces figures that understate the profitability of innovative companies, and it produces figures that are difficult to manipulate. Standard setters have consistently judged that trade worth making.
The Bottom Line
Immediate expensing of research understates the earnings and assets of the companies investing most in the future, inflates their apparent return on equity, and makes them incomparable both to acquisitive peers and to international filers. The correction is to capitalise the spending manually over an assumed life, understanding that the assumption drives the answer. The convention persists because the alternative would give management discretion over earnings precisely where the temptation to use it is greatest.